Fimaporfin

Drug Profile

Fimaporfin

Alternative Names: Amphinex; PC-A11; PC-A22; TPCS-2A

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator PCI Biotech
  • Developer Norwegian Radium Hospital; PCI Biotech; University Hospital Zurich
  • Class Antineoplastics; Benzenesulfonates; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Cholangiocarcinoma
  • Preclinical Malignant melanoma
  • Discontinued Bladder cancer; Head and neck cancer

Most Recent Events

  • 06 Sep 2016 Interim adverse events and efficacy data from a phase I/II trial in Cholangiocarcinoma released by PCI Biotech
  • 01 Sep 2016 PCI Biotech initiates enrolment in the phase I trial in healthy volunteers in the United Kingdom (NCT02947854)
  • 09 Feb 2016 Phase-I/II clinical trials in Cholangiocarcinoma (Inoperable/Unresectable) in Lithuania & Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top